Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 9/20 | 0.63 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.63 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4248266 | 0.90 | CHRM2 (0.53) | CHRM1CHRM3CHRM2PKM | |
| SCHEMBL4241897 | 0.85 | CHRM2 (0.45) | CHRM1CHRM3CHRM2PKM | |
| SCHEMBL4786760 | 0.81 | CHRM2 (0.52) | CHRM1CHRM3CHRM2ACHE | |
| SCHEMBL4248347 | 0.79 | CHRM2 (0.52) | CHRM1CHRM3CHRM2ACHEPKM | |
| SCHEMBL4240894 | 0.78 | CHRM2 (0.47) | CHRM1CHRM3CHRM2ACHEPKM | |
| SCHEMBL2830097 | 0.77 | CHRM2 (1.00) | CHRM1CHRM3CHRM2CHRM5CHRM4 | |
| SCHEMBL4250571 | 0.77 | CHRM2 (0.52) | CHRM1CHRM3CHRM2ACHE | |
| SCHEMBL4241506 | 0.77 | CHRM2 (0.48) | CHRM1CHRM3CHRM2ACHEPKM | |
| SCHEMBL4238211 | 0.75 | CHRM2 (0.47) | CHRM1CHRM3CHRM2ACHEPKM | |
| SCHEMBL4193478 | 0.74 | CACNA1G (0.43) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | claimed |
| EP-1904446-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-04-02 | — | — | EP | claimed |
| WO-2007007282-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-18 | — | — | WO | claimed |
| US-20090012116-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
| EP-1904446-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007007282-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM2, CHRM5 | CHRM1 5/4885CHRM3 1/4885CHRM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.